Emyria Ltd is a clinical-stage biotech developing treatments for mental health and neurological conditions. Emyria has developed a range of proprietary, cannabinoid-based pharmaceuticals and is leading an MDMA-inspired drug discovery program. Emyria also manages a network of specialist medical clinics that provide crucial Real-World Data that supports its drug development initiatives.
Drug Development: Emyria has developed an Ultra-Pure cannabinoid platform that can support the registration of multiple proprietary dose forms. Emyria’s first dose form, EMD-RX5 is in Phase 3 trials
New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s largest libraries of MDMA-like compounds with partner, the University of Western Australia.
Proprietary Real-World Data (RWD): Emyria gathers ethically-sourced data with patients cared for at Emyria’s own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.